Revisiting traditional Chinese materia medica from European historical collections and perspective for current use.
CMM development
CMM, Chinese materia medica
ChP 2015, Chinese Pharmacopoeia 2015 edition
Chinese materia medica
Historical CMM collections
Medicinal plant parts
TCM, traditional Chinese medicine
Traditional Chinese medicine
Journal
Journal of traditional and complementary medicine
ISSN: 2225-4110
Titre abrégé: J Tradit Complement Med
Pays: Netherlands
ID NLM: 101605474
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
22
09
2021
revised:
15
11
2021
accepted:
19
11
2021
entrez:
9
5
2022
pubmed:
10
5
2022
medline:
10
5
2022
Statut:
epublish
Résumé
Chinese Materia Medica (CMM) is subject to changes over time. Investigating changes in botanical ingredients, applications, plant parts used as well as name changes over time, contribute to the understanding of the history and development of CMM. This study compares four historic collections of CMM, located in Europe, compiled between 1700 and the late 19th century, with a list of contemporary CMM marketed in Europe. More than 1700 specimens within these five collections. The dominant families are Fabaceae (5.3-7.2%) and Asteraceae (4.1-5.7%), while half of the medicinal parts are represented by roots or rhizomes and fruits and/or seeds. Their importance has been stable in a time span of 300 years. The proportion of animal and mineral drugs gradually decreased over time. 14 plant species appeared in all five collections. A total of 47 species are shared between the three more recent collections and the modern trade list. Among these common species, most medicinal parts remain unchanged, but for several species the used plant parts changed or new medicinal plant parts appeared. All common species have unanimously been used in ancient classical TCM formulae and/or Chinese patent medicines. Over more than 300 years, the main body of CMM has hardly changed, with regard to plant taxa and plant parts used. The most prominent changes are related to conservation issues of threatened species, health safety and the discovery of new pharmacological applications of well-known species. Analyzing physical specimens from historic CMM collections complements literature-based research.
Sections du résumé
Background and aim
UNASSIGNED
Chinese Materia Medica (CMM) is subject to changes over time. Investigating changes in botanical ingredients, applications, plant parts used as well as name changes over time, contribute to the understanding of the history and development of CMM.
Materials and methods
UNASSIGNED
This study compares four historic collections of CMM, located in Europe, compiled between 1700 and the late 19th century, with a list of contemporary CMM marketed in Europe.
Results
UNASSIGNED
More than 1700 specimens within these five collections. The dominant families are Fabaceae (5.3-7.2%) and Asteraceae (4.1-5.7%), while half of the medicinal parts are represented by roots or rhizomes and fruits and/or seeds. Their importance has been stable in a time span of 300 years. The proportion of animal and mineral drugs gradually decreased over time. 14 plant species appeared in all five collections. A total of 47 species are shared between the three more recent collections and the modern trade list. Among these common species, most medicinal parts remain unchanged, but for several species the used plant parts changed or new medicinal plant parts appeared. All common species have unanimously been used in ancient classical TCM formulae and/or Chinese patent medicines.
Conclusions
UNASSIGNED
Over more than 300 years, the main body of CMM has hardly changed, with regard to plant taxa and plant parts used. The most prominent changes are related to conservation issues of threatened species, health safety and the discovery of new pharmacological applications of well-known species. Analyzing physical specimens from historic CMM collections complements literature-based research.
Identifiants
pubmed: 35528475
doi: 10.1016/j.jtcme.2021.11.001
pii: S2225-4110(21)00136-X
pmc: PMC9072815
doi:
Types de publication
Journal Article
Langues
eng
Pagination
206-216Informations de copyright
© 2021 Center for Food and Biomolecules, National Taiwan University. Production and hosting by Elsevier Taiwan LLC.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest relevant to the publication of this document.
Références
J Ethnopharmacol. 2017 Mar 22;200:209-227
pubmed: 28219727
Zhongguo Zhong Yao Za Zhi. 2015 Dec;40(24):4923-7
pubmed: 27245044
Lancet. 1993 Feb 13;341(8842):387-91
pubmed: 8094166
Pharm Biol. 2001;39 Suppl 1:8-17
pubmed: 21554167
Lancet. 1999 Aug 7;354(9177):481-2
pubmed: 10465175
Phytomedicine. 2018 Mar 15;42:219-225
pubmed: 29655689
J Ethnopharmacol. 2011 Nov 18;138(2):314-32
pubmed: 22004895
Nature. 2007 Jul 12;448(7150):126-8
pubmed: 17625539
J Ethnopharmacol. 2015 Aug 22;172:10-29
pubmed: 26087234
J Ethnopharmacol. 2009 Jul 30;124(3):350-68
pubmed: 19422901
PLoS One. 2019 Jun 26;14(6):e0217779
pubmed: 31242215
Chin Med. 2018 Apr 10;13:18
pubmed: 29651300
Biomed Pharmacother. 2020 Oct;130:110641
pubmed: 34321172
Nat Prod Rep. 2014 May;31(5):676-93
pubmed: 24691743
J Ethnopharmacol. 2021 Apr 6;269:113714
pubmed: 33352236
J Ethnopharmacol. 2018 Aug 10;222:11-20
pubmed: 29705516
Drug Metab Dispos. 2007 Jul;35(7):1217-22
pubmed: 17392392